Method for treating 5-HT.sub.2B receptor related conditions

A method for treating a mammal suffering from or susceptible to a Functional Bowel Disorder associated with abnormal or dysfunctional 5-HT.sub.2B receptor stimulation, comprising administering to the mammal an effective amount of a compound of the Formula ##STR194## wherein R.sub.8 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, halo, halo(C.sub.2 -C.sub.6)alkyl, halo(C.sub.2 -C.sub.6)alkenyl, COR.sub.5, C.sub.1 -C.sub.10 alkanoyl, CO.sub.2 R.sub.5', (C.sub.1 -C.sub.6 alkyl).sub.m amino, NO.sub.2, --SR.sub.5, OR.sub.5, C.sub.3 -C.sub.8 cycloalkyl, substituted C.sub.3 -C.sub.8 cycloalkyl, C.sub.3 -C.sub.8 cycloalkyl-(C.sub.1 -C.sub.3)alkyl, C.sub.5 -C.sub.8 cycloalkenyl, substituted C.sub.5 -C.sub.8 cycloalkenyl, C.sub.5 -C.sub.8 cycloalkenyl-(C.sub.1 -C.sub.3)alkyl, or C.sub.7 -C.sub.20 arylalkyl;

• R.sub.5 is hydrogen or C.sub.1 -C.sub.4 alkyl;
• R.sub.5' is C.sub.1 -C.sub.4 alkyl;
• m is 1 or 2;
• R.sub.9 and R.sub.10 independently are hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.8 cycloalkyl, substituted C.sub.3 -C.sub.8 cycloalkyl, C.sub.3 -C.sub.8 cycloalkyl-(C.sub.1 -C.sub.3)alkyl, C.sub.5 -C.sub.8 cycloalkenyl-(C.sub.1 -C.sub.3)alkyl, or C.sub.7 -C.sub.20 arylalkyl;
• R.sub.11 is C.sub.1 -C.sub.4 alkyl, OR.sub.5', fluoro, bromo, iodo, or chloro;
• and
• R.sub.12' is hydrogen or C.sub.1 -C.sub.4 alkyl;
• or
• a pharmaceutically acceptable salt or solvate thereof.

A method for blocking a 5-HT.sub.2B receptor in a mammal comprising administering to the mammal a 5-HT.sub.2B receptor-blocking dose of a compound of the Formula ##STR195## wherein R.sub.8 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, halo, halo(C.sub.2 -C.sub.6)alkyl, halo(C.sub.2 -C.sub.6)alkenyl, COR.sub.5, C.sub.1 -C.sub.10 alkanoyl, CO.sub.2 R.sub.5', (C.sub.1 -C.sub.6 alkyl).sub.m amino, NO.sub.2, --SR.sub.5, OR.sub.5, C.sub.3 -C.sub.8 cycloalkyl, substituted C.sub.3 -C.sub.8 cycloalkyl, C.sub.3 -C.sub.8 cycloalkyl-(C.sub.1 -C.sub.3)alkyl, C.sub.5 -C.sub.8 cycloalkenyl, substituted C.sub.5 -C.sub.8 cycloalkenyl, C.sub.5 -C.sub.8 cycloalkenyl-(C.sub.1 -C.sub.3)alkyl, or C.sub.7 -C.sub.20 arylalkyl;

• R.sub.5 is hydrogen or C.sub.1 -C.sub.4 alkyl;
• R.sub.5' is C.sub.1 -C.sub.4 alkyl;
• m is 1 or 2;
• R.sub.9 and R.sub.10 independently are hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.8 cycloalkyl, substituted C.sub.3 -C.sub.8 cycloalkyl, C.sub.3 -C.sub.8 cycloalkyl-(C.sub.1 -C.sub.3)alkyl, C.sub.5 -C.sub.8 cycloalkenyl-(C.sub.1 -C.sub.3)alkyl, or C.sub.7 -C.sub.20 arylalkyl;
• R.sub.11 is C.sub.1 -C.sub.4 alkyl, OR.sub.5', fluoro, bromo, iodo, or chloro;
• and
• R.sub.12' is hydrogen or C.sub.1 -C.sub.4 alkyl;
• or
• a pharmaceutically acceptable salt or solvate thereof.

A method for selectively blocking a 5-HT.sub.2B receptor in a mammal comprising administering to the mammal a 5-HT.sub.2B selective compound of the Formula ##STR196## wherein R.sub.8 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, halo, halo(C.sub.2 -C.sub.6)alkyl, halo(C.sub.2 -C.sub.6)alkenyl, COR.sub.5, C.sub.1 -C.sub.10 alkanoyl, CO.sub.2 R.sub.5', (C.sub.1 -C.sub.6 alkyl).sub.m amino, NO.sub.2, --SR.sub.5, OR.sub.5, C.sub.3 -C.sub.8 cycloalkyl, substituted C.sub.3 -C.sub.8 cycloalkyl, C.sub.3 -C.sub.8 cycloalkyl-(C.sub.1 -C.sub.3)alkyl, C.sub.5 -C.sub.8 cycloalkenyl, substituted C.sub.5 -C.sub.8 cycloalkenyl, C.sub.5 -C.sub.8 cycloalkenyl-(C.sub.1 -C.sub.3)alkyl, or C.sub.7 -C.sub.20 arylalkyl;

• R.sub.5 is hydrogen or C.sub.1 -C.sub.4 alkyl;
• R.sub.5' is C.sub.1 -C.sub.4 alkyl;
• m is 1 or 2;
• R.sub.9 and R.sub.10 independently are hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.8 cycloalkyl, substituted C.sub.3 -C.sub.8 cycloalkyl, C.sub.3 -C.sub.8 cycloalkyl-(C.sub.1 -C.sub.3)alkyl, C.sub.5 -C.sub.8 cycloalkenyl-(C.sub.1 -C.sub.3)alkyl, or C.sub.7 -C.sub.20 arylalkyl;
• R.sub.11 is C.sub.1 -C.sub.4 alkyl, OR.sub.5', fluoro, bromo, iodo, or chloro;
• and
• R.sub.12' is hydrogen or C.sub.1 -C.sub.4 alkyl;
• or
• a pharmaceutically acceptable salt or solvate thereof.

An article of manufacture comprising a pharmaceutical agent of the Formula ##STR197## wherein R.sub.8 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, halo, halo(C.sub.2 -C.sub.6)alkyl, halo(C.sub.2 -C.sub.6)alkenyl, COR.sub.5, C.sub.1 -C.sub.10 alkanoyl, CO.sub.2 R.sub.5', (C.sub.1 -C.sub.6 alkyl).sub.m amino, NO.sub.2, --SR.sub.5, OR.sub.5, C.sub.3 -C.sub.8 cycloalkyl, substituted C.sub.3 -C.sub.8 cycloalkyl, C.sub.3 -C.sub.8 cycloalkyl-(C.sub.1 -C.sub.3)alkyl, C.sub.5 -C.sub.8 cycloalkenyl, substituted C.sub.5 -C.sub.8 cycloalkenyl, C.sub.5 -C.sub.8 cycloalkenyl-(C.sub.1 -C.sub.3)alkyl, or C.sub.7 -C.sub.20 arylalkyl;

• R.sub.5 is hydrogen or C.sub.1 -C.sub.4 alkyl;
• R.sub.5' is C.sub.1 -C.sub.4 alkyl;
• m is 1 or 2;
• R.sub.9 and R.sub.10 independently are hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.8 cycloalkyl, substituted C.sub.3 -C.sub.8 cycloalkyl, C.sub.3 -C.sub.8 cycloalkyl-(C.sub.1 -C.sub.3)alkyl, C.sub.5 -C.sub.8 cycloalkenyl-(C.sub.1 -C.sub.3)alkyl, or C.sub.7 -C.sub.20 arylalkyl;
• R.sub.11 is C.sub.1 -C.sub.4 alkyl, OR.sub.5', fluoro, bromo, iodo, or chloro;
• and
• R.sub.12' is hydrogen or C.sub.1 -C.sub.4 alkyl;
• or a pharmaceutically acceptable salt or solvate thereof, contained within a packaging material that has a label indicating that the pharmaceutical agent can be used for treating a condition associated with dysfunctional or abnormal 5-HT.sub.2B receptor stimulation.